Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carotid Artery Diseases | 7 | 2020 | 101 | 1.920 |
Why?
|
| Dyslipidemias | 4 | 2017 | 107 | 1.640 |
Why?
|
| Hypolipidemic Agents | 6 | 2018 | 99 | 1.490 |
Why?
|
| Lipids | 4 | 2014 | 278 | 1.460 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2020 | 391 | 1.300 |
Why?
|
| Atherosclerosis | 5 | 2016 | 260 | 1.020 |
Why?
|
| Carotid Arteries | 4 | 2018 | 134 | 0.970 |
Why?
|
| Coronary Artery Disease | 4 | 2021 | 380 | 0.960 |
Why?
|
| Carotid Intima-Media Thickness | 3 | 2020 | 39 | 0.760 |
Why?
|
| Plaque, Atherosclerotic | 3 | 2018 | 60 | 0.650 |
Why?
|
| HIV Infections | 2 | 2020 | 893 | 0.650 |
Why?
|
| Heart Sounds | 2 | 2025 | 2 | 0.620 |
Why?
|
| Cause of Death | 1 | 2020 | 271 | 0.620 |
Why?
|
| American Heart Association | 1 | 2017 | 95 | 0.540 |
Why?
|
| Primary Prevention | 1 | 2017 | 82 | 0.530 |
Why?
|
| Cyclin D1 | 1 | 2016 | 84 | 0.510 |
Why?
|
| Myocardial Contraction | 1 | 2017 | 252 | 0.500 |
Why?
|
| Pericardium | 1 | 2016 | 70 | 0.490 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2016 | 153 | 0.490 |
Why?
|
| Guideline Adherence | 1 | 2017 | 239 | 0.480 |
Why?
|
| Foramen Ovale, Patent | 1 | 2015 | 19 | 0.480 |
Why?
|
| Anticholesteremic Agents | 2 | 2016 | 148 | 0.470 |
Why?
|
| Carotid Stenosis | 2 | 2012 | 116 | 0.440 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 1310 | 0.430 |
Why?
|
| Cardiovascular Diseases | 3 | 2015 | 741 | 0.430 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2012 | 3499 | 0.430 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2016 | 177 | 0.420 |
Why?
|
| Adipose Tissue | 1 | 2016 | 267 | 0.420 |
Why?
|
| Azetidines | 2 | 2016 | 37 | 0.420 |
Why?
|
| Thrombosis | 2 | 2015 | 311 | 0.420 |
Why?
|
| Heart Diseases | 1 | 2015 | 308 | 0.400 |
Why?
|
| Coronary Stenosis | 1 | 2012 | 39 | 0.400 |
Why?
|
| Jejunum | 1 | 2012 | 80 | 0.390 |
Why?
|
| Intestinal Absorption | 1 | 2012 | 125 | 0.380 |
Why?
|
| Heart Ventricles | 1 | 2017 | 795 | 0.380 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 616 | 0.380 |
Why?
|
| Hypertension | 1 | 2017 | 763 | 0.360 |
Why?
|
| MicroRNAs | 1 | 2016 | 573 | 0.360 |
Why?
|
| Cholesterol, HDL | 4 | 2017 | 171 | 0.360 |
Why?
|
| Disease Progression | 4 | 2020 | 1503 | 0.350 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1078 | 0.340 |
Why?
|
| Cholesterol, LDL | 6 | 2018 | 237 | 0.300 |
Why?
|
| Blood Glucose | 1 | 2012 | 855 | 0.300 |
Why?
|
| Middle Aged | 14 | 2020 | 27001 | 0.280 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2006 | 4 | 0.270 |
Why?
|
| Trypanosoma cruzi | 1 | 2006 | 8 | 0.270 |
Why?
|
| Humans | 25 | 2025 | 92175 | 0.260 |
Why?
|
| Lipoproteins, HDL | 1 | 2006 | 94 | 0.260 |
Why?
|
| Heart Auscultation | 1 | 2025 | 3 | 0.240 |
Why?
|
| Male | 16 | 2025 | 43858 | 0.230 |
Why?
|
| Niacin | 4 | 2016 | 37 | 0.220 |
Why?
|
| Cardiology | 1 | 2025 | 123 | 0.220 |
Why?
|
| Risk Factors | 4 | 2020 | 5697 | 0.210 |
Why?
|
| Treatment Outcome | 6 | 2018 | 8725 | 0.200 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2018 | 274 | 0.200 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 358 | 0.190 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 3768 | 0.190 |
Why?
|
| Biomarkers | 4 | 2018 | 1846 | 0.180 |
Why?
|
| Incidence | 3 | 2015 | 1654 | 0.180 |
Why?
|
| Heart Transplantation | 1 | 2006 | 773 | 0.170 |
Why?
|
| Time Factors | 4 | 2018 | 5426 | 0.170 |
Why?
|
| Cell Proliferation | 2 | 2016 | 1720 | 0.160 |
Why?
|
| Students, Medical | 1 | 2025 | 433 | 0.160 |
Why?
|
| Female | 12 | 2025 | 47822 | 0.160 |
Why?
|
| Clinical Competence | 1 | 2025 | 805 | 0.160 |
Why?
|
| Coronary Angiography | 2 | 2012 | 248 | 0.150 |
Why?
|
| Lipoprotein(a) | 1 | 2018 | 30 | 0.140 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 873 | 0.140 |
Why?
|
| Compliance | 1 | 2017 | 21 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 890 | 0.140 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 45 | 0.140 |
Why?
|
| Chest Pain | 1 | 2017 | 46 | 0.140 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2016 | 14 | 0.130 |
Why?
|
| Antigens, Nuclear | 1 | 2016 | 25 | 0.130 |
Why?
|
| Heart Failure | 1 | 2006 | 1346 | 0.130 |
Why?
|
| Linear Models | 1 | 2017 | 427 | 0.130 |
Why?
|
| Melanocytes | 1 | 2016 | 57 | 0.130 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 96 | 0.130 |
Why?
|
| Proprotein Convertases | 1 | 2015 | 26 | 0.120 |
Why?
|
| Immunoblotting | 1 | 2016 | 276 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2025 | 1080 | 0.120 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2015 | 18 | 0.120 |
Why?
|
| Adult | 8 | 2018 | 27494 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 994 | 0.120 |
Why?
|
| Clinical Trials as Topic | 3 | 2016 | 1148 | 0.110 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2015 | 74 | 0.110 |
Why?
|
| Cell Cycle | 1 | 2016 | 513 | 0.110 |
Why?
|
| Cisplatin | 1 | 2016 | 602 | 0.110 |
Why?
|
| Heptanoic Acids | 2 | 2011 | 71 | 0.110 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1119 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 291 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 507 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2020 | 2972 | 0.100 |
Why?
|
| Pyrroles | 2 | 2011 | 171 | 0.100 |
Why?
|
| Apoptosis | 2 | 2016 | 1742 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2020 | 2366 | 0.100 |
Why?
|
| Ezetimibe | 1 | 2012 | 36 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 807 | 0.100 |
Why?
|
| Simvastatin | 2 | 2016 | 106 | 0.100 |
Why?
|
| Melanoma | 1 | 2016 | 482 | 0.090 |
Why?
|
| Cell Line | 1 | 2016 | 2504 | 0.090 |
Why?
|
| Smoking | 1 | 2015 | 640 | 0.090 |
Why?
|
| Global Health | 1 | 2013 | 197 | 0.090 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 2667 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1898 | 0.080 |
Why?
|
| Age Factors | 1 | 2014 | 1904 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2016 | 1684 | 0.070 |
Why?
|
| Carotid Artery, Common | 1 | 2006 | 28 | 0.060 |
Why?
|
| Aged | 3 | 2018 | 19915 | 0.060 |
Why?
|
| Carotid Artery, Internal | 1 | 2006 | 70 | 0.060 |
Why?
|
| Gadolinium DTPA | 1 | 2006 | 255 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2368 | 0.060 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2006 | 165 | 0.060 |
Why?
|
| Double-Blind Method | 3 | 2018 | 1751 | 0.060 |
Why?
|
| United States | 1 | 2017 | 7338 | 0.060 |
Why?
|
| Educational Measurement | 1 | 2025 | 235 | 0.050 |
Why?
|
| Animals | 3 | 2015 | 27974 | 0.050 |
Why?
|
| Contrast Media | 1 | 2006 | 1076 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1764 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 1773 | 0.040 |
Why?
|
| Lipid Metabolism | 2 | 2011 | 212 | 0.040 |
Why?
|
| Colestipol | 1 | 2016 | 3 | 0.030 |
Why?
|
| Lovastatin | 1 | 2016 | 29 | 0.030 |
Why?
|
| Luciferases | 1 | 2016 | 129 | 0.030 |
Why?
|
| Hyperlipoproteinemias | 1 | 2015 | 7 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 138 | 0.030 |
Why?
|
| Proprotein Convertase 9 | 1 | 2015 | 26 | 0.030 |
Why?
|
| Triglycerides | 1 | 2016 | 234 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2015 | 67 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 323 | 0.030 |
Why?
|
| Receptors, LDL | 1 | 2015 | 54 | 0.030 |
Why?
|
| Streptokinase | 1 | 1995 | 12 | 0.030 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 1995 | 12 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 288 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2016 | 298 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 146 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 432 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 795 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 382 | 0.030 |
Why?
|
| Adipocytes | 1 | 2015 | 170 | 0.030 |
Why?
|
| Heart Valve Prosthesis | 1 | 1995 | 99 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 865 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 741 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 560 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2015 | 465 | 0.030 |
Why?
|
| Binding Sites | 1 | 2016 | 1128 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 968 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2015 | 265 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 1995 | 250 | 0.020 |
Why?
|
| Idaho | 1 | 2011 | 8 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 2011 | 36 | 0.020 |
Why?
|
| Washington | 1 | 2011 | 50 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 209 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 538 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2899 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2011 | 4466 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 814 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 1226 | 0.020 |
Why?
|
| Fibrosis | 1 | 2011 | 239 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2016 | 2037 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 976 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 1399 | 0.020 |
Why?
|
| Colesevelam Hydrochloride | 1 | 2007 | 11 | 0.020 |
Why?
|
| Allylamine | 1 | 2007 | 11 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6905 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 1182 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 2388 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2016 | 3508 | 0.010 |
Why?
|
| Brain | 1 | 2015 | 2337 | 0.010 |
Why?
|
| Mutation | 1 | 2015 | 4199 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1995 | 2451 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 12103 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2790 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 1995 | 303 | 0.010 |
Why?
|